Page last updated: 2024-12-04

phosphonoacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID546
CHEMBL ID50300
CHEBI ID15732
SCHEMBL ID15612
MeSH IDM0016688

Synonyms (96)

Synonym
disodium carboxymethylphosphonate
disodium phosphonoacetate
nsc-138745
disodium phosphonoacetate monohydrate
carboxymethanephosphonic acid
brn 1764355
nsc 18205
phosphonacetic acid
einecs 224-558-1
AKOS005447286
MLS000069393 ,
CHEBI:15732 ,
smr000058341
EU-0100991
7230-09-3
acetic acid, phosphono-
nsc-18205
nsc18205
36983-81-0
NCGC00014361-02
lopac-p-6909
NCGC00014361
LOPAC0_000991
fosfonet sodium
abbott 38642
NSC138745 ,
2-phosphonoacetic acid
STK372961
phosphonoacetic acid
C05682
4408-78-0
fosfonet
phosphonoacetate
1EW8
DB02823
phosphonoacetic acid, 98%
NCI138745
NCI60_000870
NCISTRUC2_000084
NCISTRUC1_000084
NCGC00094288-01
NCGC00094288-02
NCGC00094288-03
NCGC00014361-03
P 6909
7057FCB7-1B5A-4B59-B5AC-380E86F98C9D
NCGC00014361-07
CHEMBL50300
BMSE000660
inchi=1/c2h5o5p/c3-2(4)1-8(5,6)7/h1h2,(h,3,4)(h2,5,6,7)
xuyjlqhkogndpb-uhfffaoysa-
bdbm50008089
HMS3263G03
4-04-00-03612 (beilstein handbook reference)
n919e46723 ,
unii-n919e46723
A826485
cas-4408-78-0
dtxcid0025107
tox21_110045
dtxsid2045107 ,
HMS2234F14
S3356
CCG-38040
NCGC00014361-04
NCGC00014361-05
NCGC00014361-06
FT-0635275
LP00991
HMS3371G15
SCHEMBL15612
NCGC00014361-08
tox21_110045_1
NCGC00261676-01
tox21_500991
phosphonoaceticacid
fosfonoacetic acid
OPERA_ID_1619
phosphonoacetic acid, tracecert(r), 31p-qnmr standard
mfcd00004311
sr-01000076075
SR-01000076075-1
phosphonacetate
carboxymethanephosphonate
fosfonoacetate
HY-128744
Q27093778
BBL100127
SDCCGSBI-0050964.P003
NCGC00014361-09
AMY39197
CS-0102536
AS-57378
phosphonoethanoic acid
EN300-7590518
Z277558864

Research Excerpts

Overview

Phosphonoacetic acid is a selective antiherpesvirus agent. It was found to be a potent and selective inhibitor of virus DNA synthesis.

ExcerptReferenceRelevance
"Phosphonoacetic acid was found to be a potent and selective inhibitor of virus DNA synthesis only when added to infected cultures before the onset of virus DNA synthesis."( Effect of herpes simplex virus type 1 infection on the cellular DNA polymerase activities of mouse cell cultures.
Radsak, K, 1978
)
0.98
"Phosphonoacetic acid is a selective antiherpesvirus agent. "( Structure-activity studies on phosphonoacetate.
Duff, RG; Fairgrieve, JS; Herrin, TR; Mao, JC; Otis, ER; Shipkowitz, NL; von Esch, AM, 1985
)
1.71

Effects

Phosphonoacetic acid has been shown to suppress replication of DNA tumor viruses by inhibiting the activity of virus-induced DNA polymerase and consequently viral DNA synthesis.

ExcerptReferenceRelevance
"Phosphonoacetic acid has long been known to possess a restricted potential to block DNA biosynthesis."( Conjugation of phosphonoacetic acid to nucleobase promotes a mechanism-based inhibition.
Meškys, R; Mikalkėnas, A; Ravoitytė, B; Serva, S; Servienė, E; Tauraitė, D, 2018
)
1.56
"Phosphonoacetic acid has been shown to suppress replication of DNA tumor viruses by inhibiting the activity of virus-induced DNA polymerase and consequently viral DNA synthesis. "( Inhibition of activities of DNA polymerase alpha, beta, gamma, and reverse transcriptase of L1210 cells by phosphonoacetic acid.
Allaudeen, HS; Bertino, JR, 1978
)
1.91

Treatment

Phosphonoacetic acid treatment abolished protection against reinfection with parental virus. Treatment of EBV-superinfected Raji cells was associated with the accumulation, mainly in the cytosol, of an 88,000-dalton protein, p88.

ExcerptReferenceRelevance
"Phosphonoacetic acid treatment of the primary mutant-induced infection abolished the protection against reinfection with parental virus."( Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection.
Brady, E; DeStefano, E; Friedman-Kien, AE; Klein, RJ, 1980
)
0.98
"Phosphonoacetic acid treatment of EBV-superinfected Raji cells was associated with the accumulation, mainly in the cytosol, of an 88,000-dalton protein, p88, which was also recognized with anti-p105 serum, but was not detected in superinfected cells which had not been treated with phosphonoacetic acid."( p105, an Epstein-Barr virus-induced, phosphonoacetic acid-insensitive glycoprotein target of the anti-Epstein-Barr virus immune response.
Casareale, D; Humphreys, RE; Jones, W; Sairenji, T, 1983
)
1.26
"Phosphonoacetic acid-treated animals showed a reduction in the severity of disease."( In vitro and in vivo inhibition of myxoma virus by treatment with phosphonoacetic acid.
Goodrich, JM; Hinze, HC; Lee, KW, 1981
)
1.22

Toxicity

ExcerptReferenceRelevance
" No significant difference in the incidence of local or systemic adverse effects was noted between the two groups."( Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study.
Aoki, FY; Lawee, D; Portnoy, J; Rosenthal, D, 1988
)
0.27
" Adverse effects, such as decreased haemoglobin, decreased renal function and increased serum calcium, were observed in a few patients only."( Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients.
Ahlmén, J; Klintmalm, G; Lernestedt, JO; Lönnqvist, B; Paulin, T; Ringdén, O; Wahren, B, 1986
)
0.27

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic properties of PFA in young (growing) and adult specific-pathogen-free cats were compared."( Age-related differences in pharmacokinetics of phosphonoformate in cats.
Mathes, LE; Michael, DF; Polas, PJ; Sams, RA; Swenson, CL, 1990
)
0.28
" A pharmacokinetic study was carried out as part of a clinical trial designed to evaluate the safety and efficacy of intermittently administered intravenous foscarnet for the treatment of CMV retinitis."( Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989
)
0.28
" A cross-over study was conducted to determine whether PALA affects the pharmacokinetic parameters of 5-FU in patients given 5-FU/folinic acid (FA)."( Effects of PALA on the pharmacokinetics of 5-fluorouracil.
Bates, S; Cripps, MC; Fry, D; Goel, R; Molepo, JM; Nassim, MA; Obrocea, M; Redmond, D; Rouini, MR; Shirazi, FH; Stewart, DJ; Veerasinghan, S,
)
0.13
"Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements."( Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999
)
0.3

Compound-Compound Interactions

ExcerptReferenceRelevance
" The combined effect of ddNTPs and the pyrophosphate analog phosphonoformate (PFA) on HIV reverse transcriptase was also examined, and inhibition by PFA in combination with ddTTP or AZTTP was mutually exclusive."( Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.
Cheng, YC; Starnes, MC, 1989
)
0.28
" The most potent inhibitor, 3'-fluoro-3'-deoxythymidine, was shown to give synergistic inhibition of HIV-1 replication in combination with the PPi analog phosphonoformate."( Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1.
Cox, S; Gilljam, G; Harmenberg, J; Koshida, R; Wahren, B, 1989
)
0.28
" Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures."( Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Camacho, FJ; Engstrom, PF; Green, MD; Greenwald, ES; Kaplan, BH; Muggia, FM; Wernz, JC, 1987
)
0.27
" The antiCMV activity of acyclovir in combination with human fibroblast interferon (IFN-beta), phosphonoformic acid (PFA), or trifluorothymidine (TFT) was therefore evaluated."( Effects of acyclovir combined with other antiviral agents on human cytomegalovirus.
Kelley, E; Spector, SA; Tyndall, M, 1982
)
0.26
" Using such low, nontherapeutic, but biochemically active doses of PALA in combination with 5-fluorouracil (FUra(, it was possible to maintain the dose of FUra at its full maximum tolerated single agent dose."( Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
Casper, ES; Martin, DS; Sawyer, RC; Spiegelman, S; Stolfi, RL; Young, CW, 1983
)
0.27
"Modulation of the therapeutic efficacy of cisplatin (CDDP) and 5-fluoro-2'-deoxyuridine (FdUrd) alone and in combination with N-phosphonacetyl-L-aspartate (PALA) was evaluated in mice bearing colon carcinoma (C-26) using a weekly intravenous (i."( Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-L-aspartate in murine colon carcinoma no. 26.
Cao, S; Durrani, FA; Mayhew, EG; Peters, GJ; Rustum, YM; Van Laar, JA, 1995
)
0.29
"To evaluate an intracranial polymer implant containing bromodeoxyuridine (BrdUrd) and N-(phosphonacetyl)-L-aspartic acid (PALA) in combination with external beam radiotherapy (EBRT) in the treatment of a rat glioma."( Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy.
Lehnert, S; Li, Y; Owusu, A, 2004
)
0.32
"In tissue culture experiments, C6 cells were refractory to radiosensitization by BrdUrd even when the thymidine analog was combined with a biomodulator intended to reduce de novo thymidine synthesis."( Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy.
Lehnert, S; Li, Y; Owusu, A, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
" The mean oral bioavailability of encapsulated TPFA and PFA was 22 and 8%, respectively."( Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat.
Bai, SA; de Vera, CC; Loo, TL; Nelson, PD; Straw, JA; Tompkins, WA, 1992
)
0.28
" Mean oral bioavailability was 35% in young cats."( Age-related differences in pharmacokinetics of phosphonoformate in cats.
Mathes, LE; Michael, DF; Polas, PJ; Sams, RA; Swenson, CL, 1990
)
0.28
" In the rabbit the absolute bioavailability after vaginal and topical administration is 14% and 12%, respectively, and in the dog 34% and 3%, respectively."( "Body burden" of phosphonoformic acid after topical and vaginal administration to rabbits and beagle dogs.
Hussain, AS; Ritschel, WA, 1989
)
0.28
" An important direction for future clinical research is the development of more effective and less toxic therapy, as well as orally bioavailable drugs for maintenance therapy."( Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.
Jacobson, MA; Mills, J, 1988
)
0.27
" Thus, the therapeutic efficacy of oral administration at the various doses of eugeniin was similar to that of intraperitoneal administration, suggesting that the oral bioavailability of eugeniin was high with respect to absorption."( Biological characterization of eugeniin as an anti-herpes simplex virus type 1 compound in vitro and in vivo.
Hozumi, T; Kadota, S; Kurokawa, M; Namba, T; Shiraki, K; Tsurita, M, 2001
)
0.31
" The bioavailability of the inhibitor, nevertheless, often raise a significant selectivity constraint and may substantially limit the efficacy of therapy."( Conjugation of phosphonoacetic acid to nucleobase promotes a mechanism-based inhibition.
Meškys, R; Mikalkėnas, A; Ravoitytė, B; Serva, S; Servienė, E; Tauraitė, D, 2018
)
0.83
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Two monophosphonates, phosphonoformic and phosphonoacetic acids, and two bisphosphonate. 1-hydroxyethylidene-1, 1-bisphosph onate (HEBP) in a dosage of 10-30 mg P/kg b.

ExcerptRelevanceReference
" The dose-response curves for AMV and RMuLV polymerases primed with (rA)n."( Phosphonoformate inhibits reverse transcriptase.
Oberg, B; Sundquist, B, 1979
)
0.26
" A dosage of 230 mg kg-1 day-1 by continuous infusion is proposed for therapeutic trials in monkeys."( Preclinical toxicological study of phosphonoacetic acid: determination in blood by selected ion monitoring.
Bekesi, G; Hunt, R; Roboz, J; Suzuki, R, 1977
)
0.53
" Foscarnet induction therapy was administered at a dosage of 60 mg/kg 3 times/day via 1-hour intravenous infusion for 21 days."( Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
Polis, MA, 1992
)
0.28
"Data from human studies were extracted by the author and evaluated according to the patient population studied, sample size, dosage regimen, and therapeutic response."( Treatment of herpesvirus infections in HIV-infected individuals.
Fletcher, CV,
)
0.13
" It is thus difficult to formulate optimal dosing regimens on the basis of what is known of foscarnet pharmacodynamics and pharmacokinetics."( Clinical pharmacology: foscarnet.
Lietman, PS, 1992
)
0.28
" Probit plots of the dose-response data obtained for each resistant 2008 line following chronic exposure to PALA again confirmed this prediction."( Mechanism-based model for tumor drug resistance.
Chan, TC; Kuczek, T, 1992
)
0.28
" At the high infusion rate, treatment was discontinued after 1-2 days of dosing due to pronounced adverse clinical signs such as extensive vomitings, apathy, ataxia, and muscle spasms."( Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs.
Lundström, J; Nordgren, T; Ryrfeldt, A, 1992
)
0.28
" Nephrotoxicity can be minimized by adjusting dosage according to creatinine clearance and by ensuring that adequate hydration is provided throughout foscarnet therapy."( Review of the toxicities of foscarnet.
Jacobson, MA, 1992
)
0.28
" Reviewing the lessions of the PALA-FU experience, this article explains the potential benefits as well as the need for biochemical modulation in cancer chemotherapy, the need for the appropriate dosage ratio between agents in modulation-based clinical trials, and the necessity to determine in patients, by direct biochemical measurements at the tissue level, the dose and temporal relationship between agents that reproduces the pertinent biochemical changes in human tumors that produced the therapeutic success of that particular drug combination in the preclinical model."( Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.
Kemeny, NE; Martin, DS, 1992
)
0.28
"Foscarnet is a potentially effective and tolerable antiviral agent for patients with acyclovir-resistant, varicella-zoster virus infection; however, the optimal dosage and duration of therapy require further study, as does the relation between clinical findings and in-vitro susceptibility results."( Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection.
Berger, TG; Biron, KK; Gilson, I; Mills, J; Safrin, S; Wofsy, CB; Wolfe, PR, 1991
)
0.28
" In this report, the efficacy, safety, and dosing requirements of foscarnet in a hemodialysis-dependent patient with CMV retinitis are presented."( Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991
)
0.28
" Therefore we began treatment with trisodium phosphonoformate (Foscavir) at a dosage of 60 mg/kg body weight per day (3 weeks), continuing with maintenance therapy at 90 mg/kg body weight per day (7 days a week)."( [Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis].
Gümbel, H; Helm, EB; Ohrloff, C; Schalnus, R, 1991
)
0.28
" The incidence of acute renal failure, which is common during foscarnet therapy, may be reduced by dosage adjustment and adequate prehydration."( Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
Chrisp, P; Clissold, SP, 1991
)
0.28
" The serious toxicity associated with zidovudine has led researchers to develop safer dosage regimens."( Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Cersosimo, RJ; Matthews, SJ; Spivack, ML, 1991
)
0.28
" Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir."( Foscarnet sodium.
Baltz, JK; Minor, JR, 1991
)
0.28
"Disodium palmityl phosphonoformate, a novel lipid phosphoester of the anti HIV agent phosphonoformate (foscarnet), inhibits HIV replication in H9 cells and syncytia formation in MOLT-3 cells as effectively as foscarnet itself, as shown by dose-response data from assays for expression of p17 and p24 viral antigens and syncytia formation."( Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties, and interaction with plasma proteins.
Bhongle, NN; Camaioni Neto, C; Piratla, RK; Sarin, PS; Steim, JM; Sun, DK; Turcotte, JG, 1990
)
0.28
"Foscarnet, 60 mg/kg body weight intravenously every 8 hours (with reduced dosage for renal impairment), for 12 to 50 days."( Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989
)
0.28
" Additional studies to determine the optimal dosage for maintenance therapy are needed, as are comparative trials with ganciclovir."( Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Jacobson, MA; Mills, J; O'Donnell, JJ, 1989
)
0.28
" Eight patients with acquired immunodeficiency syndrome and serious CMV retinitis received 2-h intravenous infusions of foscarnet at a dosage of 60 mg/kg of body weight every 8 h for 14 days."( Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989
)
0.28
" Maintenance therapy with DHPG would appear to be necessary to prevent relapse, but the logistics of this are difficult, and the effective dosage of DHPG is as yet uncertain."( Treatment of CMV retinitis in an AIDS patient.
Acheson, JF; Bradbeer, C; Shah, SM; Spalton, DJ; Thin, RN, 1987
)
0.27
" For that reason, most patients have received continued therapy with the drug, most commonly at a dosage of 5-6 mg/(kg."( Treatment of cytomegalovirus retinitis in patients with AIDS.
Cederberg, D; Holland, GN; Jacobson, MA; Mills, J; O'Donnell, JJ,
)
0.13
" These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms."( Antiviral chemotherapy and chemoprophylaxis.
Dolin, R, 1985
)
0.27
" The dosage of Foscarnet was increased during the study."( Clinical experiences with phosphonoformate (foscarnet) treatment of viral diseases following renal transplantation.
Ahlmén, J; Brynger, H; Lycke, E; Wijnween, AC, 1985
)
0.27
", a low-PALA:high-FUra dosage ratio) have not yet been translated into clinical trial."( Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance.
Casper, ES; Martin, DS; Sawyer, RC; Spiegelman, S; Stolfi, RL; Young, CW, 1983
)
0.27
" The animals were treated twice daily in a dosage which gave a minimum serum level of PFA corresponding to an in vitro inhibiting effect on WHV DNA polymerase of about 40%."( No in vivo effect of trisodium phosphonoformate on woodchuck hepatitis virus production.
Hansson, BG; Löfgren, B; Möller-Nielsen, C; Nordenfelt, E; Oberg, B; Widell, A, 1982
)
0.26
" In a comparative study with this 3-day dosage schedule, the efficacy of daily doses of 50 mg of FMAU per kg was greater than that of the same doses of FIAC and FIAU, in that order; all these were more effective than daily doses of 50, 100, or 200 mg of acyclovir or of 500 mg of phosphonoformic acid per kg."( Treatment of primary acute genital herpes in guinea pigs by intraperitoneal administration of fluoropyrimidines.
Hsiung, GD; Mayo, DR, 1984
)
0.27
" 5-Fluorouracil at high dosage may cause cerebellar ataxia, but may also do so at low dosage when combined with thymidine infusions."( Neurological complications of antineoplastic therapy.
Shapiro, WR; Young, DF, 1984
)
0.27
"Thirty-six patients with advanced carcinoma of the cervix received PALA at a dosage of 5 gm/m2 every three weeks."( PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.
Beecham, J; Bundy, B; DiSaia, PJ; Muss, HB; Stehman, FB, 1984
)
0.27
" High doses of PALA (1 to 2 g/sq m) prevented the use of full dosage of FUra; however, PALA (250 mg/sq m) can be administered 24 hr before FUra (750 mg/sq m) once weekly for at least 3 weeks."( Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Casper, ES; Martin, DS; Vale, K; Williams, LJ; Young, CW, 1983
)
0.27
" In low multiplicity of infection (MOI) (10(-3) or less) infected Pekin duck and chicken fibroblast cultures, the dosage required for a 50% plaque reduction was approximately 20 microgram/ml."( Inhibition of Anatid herpesvirus replication by phosphonoacetate.
Attanasio, R; Campen, R; Johnson, JC; Olson, R, 1981
)
0.26
" Low dose and either continuous infusion or repetitive dosing of leucovorin, as well as the effect of treatment sequence and intervals between drugs, require additional investigation."( Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
Allegra, CJ; Grogan, L; Sotos, GA, 1994
)
0.29
" Treatment was well tolerated; 4/27 patients experienced > or = ECOG grade 3 toxicity at full 5-FU dosage (500 mg/m2 bolus/infusion)."( A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Kerr, DJ; Oster, W; Steward, WP; Yosef, H, 1994
)
0.29
" Clonal lines resistant to hypertonic NaCl or to hypertonic mannitol were cross-resistant in dose-response tests with graded PALA."( Evidence that resistance to osmotic stress is mediated by gene amplification.
Harris, M, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antiviral agentA substance that destroys or inhibits replication of viruses.
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitorA DNA polymerase inhibitor that interferes with the action of a DNA-directed DNA polymerase (EC 2.7.7.7).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
phosphonic acidsHP(=O)(OH)2 (phosphonic acid) and its P-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (26)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency63.09570.004023.8416100.0000AID485290
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
endonuclease IVEscherichia coliPotency0.35480.707912.432431.6228AID1708
RAR-related orphan receptor gammaMus musculus (house mouse)Potency6.66850.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency33.49150.000221.22318,912.5098AID1259243
Smad3Homo sapiens (human)Potency1.25890.00527.809829.0929AID588855
DNA polymerase III, partialBacillus subtilisPotency21.19231.062114.152826.6795AID485295
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.03980.001318.074339.8107AID926
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency15.48710.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency0.28180.28189.721235.4813AID2326
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.00700.000229.305416,493.5996AID743075
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency100.00000.707936.904389.1251AID504333
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency33.48890.023723.228263.5986AID743222
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency13.35730.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2364; AID2528
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency31.62280.001815.663839.8107AID894
importin subunit beta-1 isoform 1Homo sapiens (human)Potency0.73085.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency0.73085.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency0.73085.804816.996225.9290AID540253
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency12.58930.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency2.81840.004611.374133.4983AID624297
M-phase phosphoprotein 8Homo sapiens (human)Potency89.12510.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency0.19950.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Alkaline PhosphataseEscherichia coliKi5,500.00005,500.00005,500.00005,500.0000AID977610
Chain A, ALKALINE PHOSPHATASEEscherichia coliKi5,500.00005,500.00005,500.00005,500.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (102)

Assay IDTitleYearJournalArticle
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID127889Effect on the survival rate of mouse infected with herpes genitalis (HSV-2) administered intravaginally at 5% dosage twice in a day1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and antiherpetic activity of some 4-[(aryloxy)alkyl]pyrazoles.
AID87847Minimum inhibitory concentration causing 25% inhibition cytopathic effect induced by Herpes simplex virus-1 (Brand) in HEp-2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID88114Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -2 (thymidine kinase deficient) in HEp-2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID85571Concentration required to protect 50% of mice against a systemic infection of HSV-1.1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides.
AID85559Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 1.1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides.
AID88268Inhibitory activity against HSV-1 in vero cells2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Anti-herpes simplex virus activity of substituted 1-hydroxyacridones.
AID88118Minimum inhibitory concentration of compound causing 50% inhibition of cytopathic effect induced by HSV-2 in PRK cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID87974Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -1 (thymidine kinase deficient) in vero cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID88116Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -2 (thymidine kinase deficient) in vero cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID1128904Inhibition of red kidney beans purple acid phosphatase2014European journal of medicinal chemistry, Apr-09, Volume: 76The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.
AID87972Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus(HSV) -1 (thymidine kinase deficient) in HEp-2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID167150Minimum cytotoxic concentration causing toxic effects on uninfected cells in rabbit1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID87969Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (Brand) in vero cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID88272Therapeutic index (vero CC50/ED50) against HSV-12003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Anti-herpes simplex virus activity of substituted 1-hydroxyacridones.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID88293Therapeutic index (vero CC50/ED50) against HSV-2; NT= not tested2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Anti-herpes simplex virus activity of substituted 1-hydroxyacridones.
AID84605Concentration required to reduce the number of viral plaques in vivo cell monolayers of herpes simplex virus type 2.1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides.
AID167149Minimum cytotoxic concentration of compound causing toxic effects on uninfected cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID87331Effect on the survival rate of mouse infected with herpes genitalis (HSV-2) administered intravaginally at 2% dosage twice in a day1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and antiherpetic activity of some 4-[(aryloxy)alkyl]pyrazoles.
AID218235In vitro cytotoxic concentration in vero cells.2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Anti-herpes simplex virus activity of substituted 1-hydroxyacridones.
AID87981Minimum inhibitory concentration of compound causing 50% inhibition of cytopathic effect induced by HSV-1 (thymidine kinase deficient) in PRK cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID138121Effect on the survival rate of mouse infected with herpes genitalis (HSV-2) administered intravaginally at 5% dosage twice in a day1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and antiherpetic activity of some 4-[(aryloxy)alkyl]pyrazoles.
AID87971Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by herpes simplex virus (HSV)-1 (K979) in vero cells.1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID87970Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (K979) in HEp-2 cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID127888Effect on the survival rate of mouse infected with herpes genitalis (HSV-2) administered intravaginally at 2% dosage twice in a day1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and antiherpetic activity of some 4-[(aryloxy)alkyl]pyrazoles.
AID87982Minimum inhibitory concentration of compound causing 50% inhibition of cytopathic effect induced by HSV-1 in PRK cells1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Phosphonoformate and phosphonoacetate derivatives of 5-substituted 2'-deoxyuridines: synthesis and antiviral activity.
AID88289Inhibitory activity against HSV-2 in vero cells; NT= not tested2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Anti-herpes simplex virus activity of substituted 1-hydroxyacridones.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2000Protein science : a publication of the Protein Society, May, Volume: 9, Issue:5
Alternate modes of binding in two crystal structures of alkaline phosphatase-inhibitor complexes.
AID1811Experimentally measured binding affinity data derived from PDB2000Protein science : a publication of the Protein Society, May, Volume: 9, Issue:5
Alternate modes of binding in two crystal structures of alkaline phosphatase-inhibitor complexes.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,301)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990663 (50.96)18.7374
1990's444 (34.13)18.2507
2000's108 (8.30)29.6817
2010's75 (5.76)24.3611
2020's11 (0.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.50 (24.57)
Research Supply Index7.26 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index38.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials70 (5.15%)5.53%
Reviews99 (7.29%)6.00%
Case Studies64 (4.71%)4.05%
Observational0 (0.00%)0.25%
Other1,125 (82.84%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (25)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Modified Preemptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function [NCT01199562]153 participants (Actual)Observational2010-12-31Completed
A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China [NCT02151240]Phase 494 participants (Actual)Interventional2014-05-31Completed
A Randomised Controlled Phase II Trial of the Adoptive Transfer of Selected Cytomegalovirus-Specific Cytotoxic T Lymphocytes (CMV-CTL) After Allogeneic Stem Cell Transplantation (SCT) in Patients at Risk of CMV Disease [NCT00986557]Phase 278 participants (Anticipated)Interventional2009-09-30Recruiting
Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring [NCT00947141]Phase 4165 participants (Actual)Interventional2003-02-28Completed
A Phase I Open-Labeled Study of Long Term Combined or Alternating Foscarnet/Ganciclovir Maintenance Therapy for AIDS Patients With CMV Retinitis After Ganciclovir Induction Therapy [NCT00000970]Phase 130 participants InterventionalCompleted
Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome [NCT00000726]Phase 153 participants InterventionalCompleted
Intermittent Foscarnet Therapy for Human Immunodeficiency Virus Infection in Patients Receiving Long-Term Zidovudine Therapy [NCT00001002]Phase 112 participants InterventionalCompleted
Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine [NCT00000985]Phase 326 participants InterventionalCompleted
An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies [NCT00002021]0 participants InterventionalCompleted
An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients [NCT00002039]0 participants InterventionalCompleted
Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component [NCT00000665]240 participants InterventionalCompleted
Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease [NCT00002145]Phase 3145 participants InterventionalCompleted
Foscarnet Treatment of Cytomegalovirus (CMV) Retinitis in AIDS Patients Not Eligible for Ganciclovir Therapy and Ganciclovir Treatment Failures [NCT00002301]0 participants InterventionalActive, not recruiting
A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease [NCT00000729]Phase 110 participants InterventionalCompleted
CMV Retinitis Retreatment Trial [NCT00000766]Phase 2300 participants InterventionalCompleted
A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease. [NCT00000856]Phase 10 participants (Actual)InterventionalWithdrawn
The Effect of Increasing Gastric pH Upon the Bioavailability of Orally Administered Phosphonoformic Acid (Foscarnet) [NCT00000964]Phase 16 participants InterventionalCompleted
Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study [NCT00002146]Phase 412 participants InterventionalCompleted
An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies [NCT00002272]0 participants InterventionalCompleted
The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment [NCT00002144]Phase 112 participants InterventionalCompleted
An Open Study of Foscarnet Treatment of CMV-Retinitis in AIDS Patients [NCT00002432]0 participants InterventionalCompleted
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure [NCT00000691]Phase 2156 participants InterventionalCompleted
A Phase II Randomized Controlled Trial of Immediate Versus Delayed Foscarnet Therapy in AIDS Patients With Non-Immediately Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due to Myelosuppression [NCT00000697]Phase 20 participants (Actual)InterventionalWithdrawn
A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) [NCT00002125]Phase 4112 participants InterventionalCompleted
A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis [NCT00001061]Phase 2167 participants InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]